FAAH and Parkinson disease: This could be due to the high heterogeneity between studies which included genetic-based and toxin-based PD models and the use of a variety of cannabinoids (two CBR agonists, three MAGL/FAAH inhibitor or endocannabinoid modulator) or more significantly, had variations in how the open field tests were undertaken in each included study.